IL-23 inhibitor risankizumab induces remission in Phase II study in patients with moderate-to-severe Crohn’s disease
INGELHEIM, Germany & NORTH CHICAGO, Ill.–(BUSINESS WIRE)– Results were presented today from a proof-of-concept, Phase II, randomized, placebo-controlled study (NCT02031276) in Crohn’s disease with investigational...